IL-6 is a biomarker for inflammation linked to higher risk of cardiovascular events [23].CHF patients have higher levels of circulating IL-6.The degree of left ventricular dysfunction is correlated with IL-6 levels, which are also highly predictive of subsequent clinical outcomes [39].Doxorubicin upregulates the expressions of pro-inflammatory cytokines, including IL-6, through activation of the Nuclear factor kappa B (NF-κB), triggering the progression of adverse cardiac events [40]. Here, IL6 is linked to congestive heart failure.